Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 17;43(1):168–179. doi: 10.1080/0886022X.2020.1870139

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 6. — 15-Hydroxyprostaglandin dehydrogenase inhibition changes the level of prostaglandin E₂ (PGE2) receptor (EP) expression in kidney tissue. The protective effects of the15-PGDH inhibitor, SW033291, can be blocked by an EP4 antagonist, ONO-AE3-208. (A–D) Statistical analyses of the EP expression level. (E–G) Serum levels of creatinine, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1) due to the absence or presence of ONO-AE3-208 in the contrast-induced acute kidney injury model. (H) Statistical analyses of renal blood flow. *p < 0.05; **p < 0.01; ***p < 0.001; CM: contrast medium.